1、中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会．慢性阻塞性肺疾病诊治指南（2021年修订版）［J］．中华结核和呼吸杂志，2021，44（3）：170-205．中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会．慢性阻塞性肺疾病诊治指南（2021年修订版）［J］．中华结核和呼吸杂志，2021，44（3）：170-205．
2、张希春，刘晓芳，白澎，等．慢性阻塞性肺疾病稳定期患者外周血嗜酸性粒细胞表型及临床特征分析［J］．临床内科杂志，2023，40（7）：462-465．张希春，刘晓芳，白澎，等．慢性阻塞性肺疾病稳定期患者外周血嗜酸性粒细胞表型及临床特征分析［J］．临床内科杂志，2023，40（7）：462-465．
3、中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会．慢性阻塞性肺疾病急性加重高风险患者识别与管理中国专家共识［J］．国际呼吸杂志，2022，42（24）：1845-1863．中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会．慢性阻塞性肺疾病急性加重高风险患者识别与管理中国专家共识［J］．国际呼吸杂志，2022，42（24）：1845-1863．
4、%E5%A4%8F%E8%93%89%EF%BC%8C%E5%AD%99%E9%B9%8F%EF%BC%8C%E5%A7%9A%E6%AC%A3%20%EF%BC%8E%E6%85%A2%E6%80%A7%E9%98%BB%E5%A1%9E%E6%80%A7%E8%82%BA%E7%96%BE%E7%97%85%E2%80%832%E2%80%83%E5%9E%8B%E7%82%8E%E7%97%87%E7%9B%B8%E5%85%B3%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E4%B8%AD%E5%8D%8E%E5%81%A5%E5%BA%B7%E7%AE%A1%E7%90%86%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%8C2023%EF%BC%8C17%EF%BC%884%EF%BC%89%EF%BC%9A311-315%EF%BC%8E%E5%A4%8F%E8%93%89%EF%BC%8C%E5%AD%99%E9%B9%8F%EF%BC%8C%E5%A7%9A%E6%AC%A3%20%EF%BC%8E%E6%85%A2%E6%80%A7%E9%98%BB%E5%A1%9E%E6%80%A7%E8%82%BA%E7%96%BE%E7%97%85%E2%80%832%E2%80%83%E5%9E%8B%E7%82%8E%E7%97%87%E7%9B%B8%E5%85%B3%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E4%B8%AD%E5%8D%8E%E5%81%A5%E5%BA%B7%E7%AE%A1%E7%90%86%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%8C2023%EF%BC%8C17%EF%BC%884%EF%BC%89%EF%BC%9A311-315%EF%BC%8E
5、WU%E2%80%83C%EF%BC%8EResearch%E2%80%83%20progress%E2%80%83%20of%E2%80%83%20serum%E2%80%83%20eosinophil%E2%80%83in%E2%80%83%0Achronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83disease%E2%80%83and%E2%80%83asthma%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AOpen%E2%80%83Life%E2%80%83Sci%EF%BC%8C2023%EF%BC%8C18%EF%BC%881%EF%BC%89%EF%BC%9A20220779%EF%BC%8EWU%E2%80%83C%EF%BC%8EResearch%E2%80%83%20progress%E2%80%83%20of%E2%80%83%20serum%E2%80%83%20eosinophil%E2%80%83in%E2%80%83%0Achronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83disease%E2%80%83and%E2%80%83asthma%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AOpen%E2%80%83Life%E2%80%83Sci%EF%BC%8C2023%EF%BC%8C18%EF%BC%881%EF%BC%89%EF%BC%9A20220779%EF%BC%8E
6、WHITTAKER%E2%80%83H%E2%80%83R%EF%BC%8CM%C3%9CLLEROVA%E2%80%83H%EF%BC%8CJARVIS%E2%80%83D%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EInhaled%E2%80%83corticosteroids%EF%BC%8Cblood%E2%80%83eosinophils%EF%BC%8C%0Aand%E2%80%83FEV1%E2%80%83decline%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83COPD%E2%80%83in%E2%80%83a%E2%80%83large%E2%80%83UK%E2%80%83%0Aprimary%E2%80%83health%E2%80%83care%E2%80%83setting%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Chron%E2%80%83Obstruct%E2%80%83%0APulmon%E2%80%83Dis%EF%BC%8C2019%EF%BC%8814%EF%BC%89%EF%BC%9A1063%E2%80%83-%E2%80%831073%EF%BC%8EWHITTAKER%E2%80%83H%E2%80%83R%EF%BC%8CM%C3%9CLLEROVA%E2%80%83H%EF%BC%8CJARVIS%E2%80%83D%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EInhaled%E2%80%83corticosteroids%EF%BC%8Cblood%E2%80%83eosinophils%EF%BC%8C%0Aand%E2%80%83FEV1%E2%80%83decline%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83COPD%E2%80%83in%E2%80%83a%E2%80%83large%E2%80%83UK%E2%80%83%0Aprimary%E2%80%83health%E2%80%83care%E2%80%83setting%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Chron%E2%80%83Obstruct%E2%80%83%0APulmon%E2%80%83Dis%EF%BC%8C2019%EF%BC%8814%EF%BC%89%EF%BC%9A1063%E2%80%83-%E2%80%831073%EF%BC%8E
7、ISANTOSTEFANO%E2%80%83R%E2%80%83L%EF%BC%8CHINDS%E2%80%83D%EF%BC%8CLE%E2%80%83H%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ARelationship%E2%80%83%20between%E2%80%83%20blood%E2%80%83eosinophils%E2%80%83and%E2%80%83clinical%E2%80%83%0Acharacteristics%E2%80%83in%E2%80%83%20a%E2%80%83%20cross-sectional%E2%80%83%20study%E2%80%83%20of%E2%80%83%20a%E2%80%83US%E2%80%83%0Apopulation-based%E2%80%83COPD%E2%80%83cohort%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERespir%E2%80%83Med%EF%BC%8C%0A2016%EF%BC%88112%EF%BC%89%EF%BC%9A88%E2%80%83-%E2%80%8396%EF%BC%8EISANTOSTEFANO%E2%80%83R%E2%80%83L%EF%BC%8CHINDS%E2%80%83D%EF%BC%8CLE%E2%80%83H%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ARelationship%E2%80%83%20between%E2%80%83%20blood%E2%80%83eosinophils%E2%80%83and%E2%80%83clinical%E2%80%83%0Acharacteristics%E2%80%83in%E2%80%83%20a%E2%80%83%20cross-sectional%E2%80%83%20study%E2%80%83%20of%E2%80%83%20a%E2%80%83US%E2%80%83%0Apopulation-based%E2%80%83COPD%E2%80%83cohort%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERespir%E2%80%83Med%EF%BC%8C%0A2016%EF%BC%88112%EF%BC%89%EF%BC%9A88%E2%80%83-%E2%80%8396%EF%BC%8E
8、WU%E2%80%83C%E2%80%83W%EF%BC%8CLAN%E2%80%83C%E2%80%83C%EF%BC%8CHSIEH%E2%80%83P%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8ERole%E2%80%83%20of%E2%80%83%0Aperipheral%E2%80%83eosinophilia%E2%80%83in%E2%80%83acute%E2%80%83exacerbation%E2%80%83of%E2%80%83chronic%E2%80%83%0Aobstructive%E2%80%83pulmonary%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8EWorld%E2%80%83%20J%E2%80%83Clin%E2%80%83%0ACases%EF%BC%8C2020%EF%BC%8C8%EF%BC%8813%EF%BC%89%EF%BC%9A2727%E2%80%83-%E2%80%832737%EF%BC%8EWU%E2%80%83C%E2%80%83W%EF%BC%8CLAN%E2%80%83C%E2%80%83C%EF%BC%8CHSIEH%E2%80%83P%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8ERole%E2%80%83%20of%E2%80%83%0Aperipheral%E2%80%83eosinophilia%E2%80%83in%E2%80%83acute%E2%80%83exacerbation%E2%80%83of%E2%80%83chronic%E2%80%83%0Aobstructive%E2%80%83pulmonary%E2%80%83disease%EF%BC%BBJ%EF%BC%BD%EF%BC%8EWorld%E2%80%83%20J%E2%80%83Clin%E2%80%83%0ACases%EF%BC%8C2020%EF%BC%8C8%EF%BC%8813%EF%BC%89%EF%BC%9A2727%E2%80%83-%E2%80%832737%EF%BC%8E
9、WANG%E2%80%83R%EF%BC%8CZHAO%E2%80%83Y%EF%BC%8CXU%E2%80%83J%EF%BC%8EClinical%E2%80%83features%E2%80%83%20and%E2%80%83%0Athree-year%E2%80%83prognosis%E2%80%83of%E2%80%83AECOPD%E2%80%83patients%E2%80%83with%E2%80%83different%E2%80%83%0Alevels%E2%80%83of%E2%80%83blood%E2%80%83eosinophils%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeart%E2%80%83Lung%EF%BC%8C2022%0A%EF%BC%8856%EF%BC%89%EF%BC%9A29-39%EF%BC%8EWANG%E2%80%83R%EF%BC%8CZHAO%E2%80%83Y%EF%BC%8CXU%E2%80%83J%EF%BC%8EClinical%E2%80%83features%E2%80%83%20and%E2%80%83%0Athree-year%E2%80%83prognosis%E2%80%83of%E2%80%83AECOPD%E2%80%83patients%E2%80%83with%E2%80%83different%E2%80%83%0Alevels%E2%80%83of%E2%80%83blood%E2%80%83eosinophils%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeart%E2%80%83Lung%EF%BC%8C2022%0A%EF%BC%8856%EF%BC%89%EF%BC%9A29-39%EF%BC%8E
10、赵艳红，王传萍．哮喘表型中CD4+T细胞亚群的研究综述：分子机制和生物治疗选择［J］．上海交通大学学报（医学版），2023，43（8）：1064-1070．赵艳红，王传萍．哮喘表型中CD4+T细胞亚群的研究综述：分子机制和生物治疗选择［J］．上海交通大学学报（医学版），2023，43（8）：1064-1070．
11、中华医学会呼吸病学分会．支气管哮喘防治指南（2024年版）［J］．中华结核和呼吸杂志，2025，48（3）：208-248．中华医学会呼吸病学分会．支气管哮喘防治指南（2024年版）［J］．中华结核和呼吸杂志，2025，48（3）：208-248．
12、慢性阻塞性肺疾病急性加重诊治专家组．慢性阻塞性肺疾病急性加重诊治中国专家共识［J］．国际呼吸杂志，2023，43（2）：132-149．慢性阻塞性肺疾病急性加重诊治专家组．慢性阻塞性肺疾病急性加重诊治中国专家共识［J］．国际呼吸杂志，2023，43（2）：132-149．
13、%E2%80%83%20VESTBO%E2%80%83J%EF%BC%8CPAPI%E2%80%83A%EF%BC%8CCORRADI%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8ESingle%E2%80%83%0Ainhaler%E2%80%83%20extrafine%E2%80%83triple%E2%80%83therapy%E2%80%83%20versus%E2%80%83long-acting%E2%80%83%0Amuscarinic%E2%80%83antagonist%E2%80%83therapy%E2%80%83for%E2%80%83chronic%E2%80%83obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%88TRINITY%EF%BC%89%EF%BC%9AA%E2%80%83double-blind%EF%BC%8C%0Aparallel%E2%80%83group%EF%BC%8Crandomised%E2%80%83controlled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ALancet%EF%BC%8C2017%EF%BC%8C389%EF%BC%8810082%EF%BC%89%EF%BC%9A1919-1929%EF%BC%8E%E2%80%83%20VESTBO%E2%80%83J%EF%BC%8CPAPI%E2%80%83A%EF%BC%8CCORRADI%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8ESingle%E2%80%83%0Ainhaler%E2%80%83%20extrafine%E2%80%83triple%E2%80%83therapy%E2%80%83%20versus%E2%80%83long-acting%E2%80%83%0Amuscarinic%E2%80%83antagonist%E2%80%83therapy%E2%80%83for%E2%80%83chronic%E2%80%83obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%88TRINITY%EF%BC%89%EF%BC%9AA%E2%80%83double-blind%EF%BC%8C%0Aparallel%E2%80%83group%EF%BC%8Crandomised%E2%80%83controlled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ALancet%EF%BC%8C2017%EF%BC%8C389%EF%BC%8810082%EF%BC%89%EF%BC%9A1919-1929%EF%BC%8E
14、FERGUSON%E2%80%83G%E2%80%83T%EF%BC%8CRABE%E2%80%83K%E2%80%83F%EF%BC%8CMARTINEZ%E2%80%83F%E2%80%83J%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ETriple%E2%80%83therapy%E2%80%83with%E2%80%83budesonide%2Fglycopyrrolate%2F%0Aformoterol%E2%80%83%20fumarate%E2%80%83%20with%E2%80%83%20co-suspension%E2%80%83%20delivery%E2%80%83%0Atechnology%E2%80%83versus%E2%80%83dual%E2%80%83therapies%E2%80%83in%E2%80%83chronic%E2%80%83obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%88KRONOS%EF%BC%89%EF%BC%9AA%E2%80%83double-blind%EF%BC%8C%0Aparallel-group%EF%BC%8Cmulticentre%EF%BC%8Cphase%E2%80%83%203%E2%80%83%20randomised%E2%80%83%0Acontrolled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%E2%80%83Respir%E2%80%83Med%EF%BC%8C2018%E2%80%83%EF%BC%8C6%0A%EF%BC%8810%EF%BC%89%EF%BC%9A747-758%EF%BC%8EFERGUSON%E2%80%83G%E2%80%83T%EF%BC%8CRABE%E2%80%83K%E2%80%83F%EF%BC%8CMARTINEZ%E2%80%83F%E2%80%83J%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ETriple%E2%80%83therapy%E2%80%83with%E2%80%83budesonide%2Fglycopyrrolate%2F%0Aformoterol%E2%80%83%20fumarate%E2%80%83%20with%E2%80%83%20co-suspension%E2%80%83%20delivery%E2%80%83%0Atechnology%E2%80%83versus%E2%80%83dual%E2%80%83therapies%E2%80%83in%E2%80%83chronic%E2%80%83obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%88KRONOS%EF%BC%89%EF%BC%9AA%E2%80%83double-blind%EF%BC%8C%0Aparallel-group%EF%BC%8Cmulticentre%EF%BC%8Cphase%E2%80%83%203%E2%80%83%20randomised%E2%80%83%0Acontrolled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%E2%80%83Respir%E2%80%83Med%EF%BC%8C2018%E2%80%83%EF%BC%8C6%0A%EF%BC%8810%EF%BC%89%EF%BC%9A747-758%EF%BC%8E
15、%E2%80%83%20RAMAKRISHNAN%E2%80%83S%EF%BC%8CJEFFERS%E2%80%83H%EF%BC%8CLANGFORD%02WILEY%E2%80%83B%EF%BC%8Cet%E2%80%83al%EF%BC%8EBlood%E2%80%83%20eosinophil-guided%E2%80%83%20oral%E2%80%83%0Aprednisolone%E2%80%83%20for%E2%80%83%20COPD%E2%80%83%20exacerbations%E2%80%83%20in%E2%80%83%20primary%E2%80%83care%E2%80%83in%E2%80%83the%E2%80%83UK%EF%BC%88STARR2%EF%BC%89%EF%BC%9AA%E2%80%83non-inferiority%EF%BC%8C%0Amulticentre%EF%BC%8Cdouble-blind%EF%BC%8Cplacebo-controlled%EF%BC%8C%0Arandomised%E2%80%83controlled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%E2%80%83%20Respir%E2%80%83%0AMed%EF%BC%8C2024%EF%BC%8C12%EF%BC%881%EF%BC%89%EF%BC%9A67-77%EF%BC%8E%E2%80%83%20RAMAKRISHNAN%E2%80%83S%EF%BC%8CJEFFERS%E2%80%83H%EF%BC%8CLANGFORD%02WILEY%E2%80%83B%EF%BC%8Cet%E2%80%83al%EF%BC%8EBlood%E2%80%83%20eosinophil-guided%E2%80%83%20oral%E2%80%83%0Aprednisolone%E2%80%83%20for%E2%80%83%20COPD%E2%80%83%20exacerbations%E2%80%83%20in%E2%80%83%20primary%E2%80%83care%E2%80%83in%E2%80%83the%E2%80%83UK%EF%BC%88STARR2%EF%BC%89%EF%BC%9AA%E2%80%83non-inferiority%EF%BC%8C%0Amulticentre%EF%BC%8Cdouble-blind%EF%BC%8Cplacebo-controlled%EF%BC%8C%0Arandomised%E2%80%83controlled%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%E2%80%83%20Respir%E2%80%83%0AMed%EF%BC%8C2024%EF%BC%8C12%EF%BC%881%EF%BC%89%EF%BC%9A67-77%EF%BC%8E
16、BAFADHEL%E2%80%83M%EF%BC%8CMCKENNA%E2%80%83S%EF%BC%8CTERRY%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAcute%E2%80%83exacerbations%E2%80%83of%E2%80%83chronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83%0Adisease%EF%BC%9AIdentification%E2%80%83of%E2%80%83%20biologic%E2%80%83clusters%E2%80%83and%E2%80%83their%E2%80%83%0Abiomarkers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAm%E2%80%83J%E2%80%83Respir%E2%80%83Crit%E2%80%83Care%E2%80%83Med%EF%BC%8C%0A2011%EF%BC%8C184%EF%BC%886%EF%BC%89%EF%BC%9A662-71%EF%BC%8EBAFADHEL%E2%80%83M%EF%BC%8CMCKENNA%E2%80%83S%EF%BC%8CTERRY%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAcute%E2%80%83exacerbations%E2%80%83of%E2%80%83chronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83%0Adisease%EF%BC%9AIdentification%E2%80%83of%E2%80%83%20biologic%E2%80%83clusters%E2%80%83and%E2%80%83their%E2%80%83%0Abiomarkers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAm%E2%80%83J%E2%80%83Respir%E2%80%83Crit%E2%80%83Care%E2%80%83Med%EF%BC%8C%0A2011%EF%BC%8C184%EF%BC%886%EF%BC%89%EF%BC%9A662-71%EF%BC%8E
17、COUILLARD%E2%80%83S%EF%BC%8CLARIV%C3%89E%E2%80%83P%EF%BC%8CCOURTEAU%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AEosinophils%E2%80%83in%E2%80%83COPD%E2%80%83exacerbations%E2%80%83are%E2%80%83associated%E2%80%83with%E2%80%83%0Aincreased%E2%80%83readmissions%EF%BC%BBJ%EF%BC%BD%EF%BC%8EChest%EF%BC%8C2017%EF%BC%8C151%0A%EF%BC%882%EF%BC%89%EF%BC%9A366-373%EF%BC%8ECOUILLARD%E2%80%83S%EF%BC%8CLARIV%C3%89E%E2%80%83P%EF%BC%8CCOURTEAU%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AEosinophils%E2%80%83in%E2%80%83COPD%E2%80%83exacerbations%E2%80%83are%E2%80%83associated%E2%80%83with%E2%80%83%0Aincreased%E2%80%83readmissions%EF%BC%BBJ%EF%BC%BD%EF%BC%8EChest%EF%BC%8C2017%EF%BC%8C151%0A%EF%BC%882%EF%BC%89%EF%BC%9A366-373%EF%BC%8E
18、褚小娟，杨文婷，唐连涛，等．新型抗嗜酸性粒细胞药物在哮喘中应用的研究进展［J］．中国医药，2024，19（6）：924-927．褚小娟，杨文婷，唐连涛，等．新型抗嗜酸性粒细胞药物在哮喘中应用的研究进展［J］．中国医药，2024，19（6）：924-927．
19、广州医科大学附属第一医院国家呼吸医学中心，国家呼吸系统疾病临床医学研究中心，中华医学会呼吸病学分会哮喘学组 ．嗜酸粒细胞增多相关性肺疾病诊疗中国专家共识［J］．中华医学杂志，2022，102（1）：21-35．广州医科大学附属第一医院国家呼吸医学中心，国家呼吸系统疾病临床医学研究中心，中华医学会呼吸病学分会哮喘学组 ．嗜酸粒细胞增多相关性肺疾病诊疗中国专家共识［J］．中华医学杂志，2022，102（1）：21-35．
20、%E2%80%83%20LYU%E2%80%83M%EF%BC%8CQIANG%E2%80%83L%EF%BC%8CLI%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20lower%E2%80%83%20the%E2%80%83%0Aeosinophils%EF%BC%8Cthe%E2%80%83%20stronger%E2%80%83the%E2%80%83inflammatory%E2%80%83%20response%E2%80%83%E2%80%83%E2%80%83%0AThe%E2%80%83%20relationship%E2%80%83%20of%E2%80%83%20different%E2%80%83levels%E2%80%83%20of%E2%80%83%20eosinophils%E2%80%83%0Awith%E2%80%83the%E2%80%83degree%E2%80%83of%E2%80%83inflammation%E2%80%83in%E2%80%83acute%E2%80%83exacerbation%E2%80%83%0Achronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83disease%EF%BC%88AECOPD%EF%BC%89%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Thorac%E2%80%83Dis%EF%BC%8C2021%EF%BC%8C13%EF%BC%881%EF%BC%89%EF%BC%9A232-243%EF%BC%8E%E2%80%83%20LYU%E2%80%83M%EF%BC%8CQIANG%E2%80%83L%EF%BC%8CLI%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20lower%E2%80%83%20the%E2%80%83%0Aeosinophils%EF%BC%8Cthe%E2%80%83%20stronger%E2%80%83the%E2%80%83inflammatory%E2%80%83%20response%E2%80%83%E2%80%83%E2%80%83%0AThe%E2%80%83%20relationship%E2%80%83%20of%E2%80%83%20different%E2%80%83levels%E2%80%83%20of%E2%80%83%20eosinophils%E2%80%83%0Awith%E2%80%83the%E2%80%83degree%E2%80%83of%E2%80%83inflammation%E2%80%83in%E2%80%83acute%E2%80%83exacerbation%E2%80%83%0Achronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83disease%EF%BC%88AECOPD%EF%BC%89%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Thorac%E2%80%83Dis%EF%BC%8C2021%EF%BC%8C13%EF%BC%881%EF%BC%89%EF%BC%9A232-243%EF%BC%8E
21、ROBINSON%E2%80%83D%EF%BC%8CHUMBERT%E2%80%83M%EF%BC%8CBUHL%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ARevisiting%E2%80%83%20Type%E2%80%83%202-high%E2%80%83%20and%E2%80%83%20Type%E2%80%83%202-low%E2%80%83%20airway%E2%80%83%0Ainflammation%E2%80%83in%E2%80%83asthma%EF%BC%9ACurrent%E2%80%83%20knowledge%E2%80%83%20and%E2%80%83%0Atherapeutic%E2%80%83implications%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Exp%E2%80%83Allergy%EF%BC%8C%0A2017%EF%BC%8C47%EF%BC%882%EF%BC%89%EF%BC%9A161-175%EF%BC%8EROBINSON%E2%80%83D%EF%BC%8CHUMBERT%E2%80%83M%EF%BC%8CBUHL%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ARevisiting%E2%80%83%20Type%E2%80%83%202-high%E2%80%83%20and%E2%80%83%20Type%E2%80%83%202-low%E2%80%83%20airway%E2%80%83%0Ainflammation%E2%80%83in%E2%80%83asthma%EF%BC%9ACurrent%E2%80%83%20knowledge%E2%80%83%20and%E2%80%83%0Atherapeutic%E2%80%83implications%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Exp%E2%80%83Allergy%EF%BC%8C%0A2017%EF%BC%8C47%EF%BC%882%EF%BC%89%EF%BC%9A161-175%EF%BC%8E
22、王心怡，杨阳．嗜酸性粒细胞在PRISm发生发展中作用的研究进展［J］．临床肺科杂志，2025，30（2）：287-292．王心怡，杨阳．嗜酸性粒细胞在PRISm发生发展中作用的研究进展［J］．临床肺科杂志，2025，30（2）：287-292．
23、BUSSE%E2%80%83W%E2%80%83W%EF%BC%8CVISWANATHAN%E2%80%83R%EF%BC%8EWhat%E2%80%83%20has%E2%80%83%20been%E2%80%83%0Alearned%E2%80%83by%E2%80%83cytokine%E2%80%83targeting%E2%80%83of%E2%80%83asthma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0AAllergy%E2%80%83Clin%E2%80%83Immunol%EF%BC%8C2022%EF%BC%8C150%EF%BC%882%EF%BC%89%EF%BC%9A235-249%EF%BC%8EBUSSE%E2%80%83W%E2%80%83W%EF%BC%8CVISWANATHAN%E2%80%83R%EF%BC%8EWhat%E2%80%83%20has%E2%80%83%20been%E2%80%83%0Alearned%E2%80%83by%E2%80%83cytokine%E2%80%83targeting%E2%80%83of%E2%80%83asthma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0AAllergy%E2%80%83Clin%E2%80%83Immunol%EF%BC%8C2022%EF%BC%8C150%EF%BC%882%EF%BC%89%EF%BC%9A235-249%EF%BC%8E
24、LI%E2%80%83S%EF%BC%8CWANG%E2%80%83S%EF%BC%8CFORDJOUR%E2%80%83E%EF%BC%8Cet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83%0Aand%E2%80%83characterization%E2%80%83of%E2%80%83anti-IL-5%E2%80%83monoclonal%E2%80%83antibody%E2%80%83%0AFab%E2%80%83fragment%E2%80%83for%E2%80%83blocking%E2%80%83IL-5%2FIL-5R%CE%B1%E2%80%83binding%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AInt%E2%80%83Immunopharmacol%EF%BC%8C2023%EF%BC%8C124%EF%BC%88Pt%E2%80%83B%EF%BC%89%EF%BC%9A111032%EF%BC%8ELI%E2%80%83S%EF%BC%8CWANG%E2%80%83S%EF%BC%8CFORDJOUR%E2%80%83E%EF%BC%8Cet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83%0Aand%E2%80%83characterization%E2%80%83of%E2%80%83anti-IL-5%E2%80%83monoclonal%E2%80%83antibody%E2%80%83%0AFab%E2%80%83fragment%E2%80%83for%E2%80%83blocking%E2%80%83IL-5%2FIL-5R%CE%B1%E2%80%83binding%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AInt%E2%80%83Immunopharmacol%EF%BC%8C2023%EF%BC%8C124%EF%BC%88Pt%E2%80%83B%EF%BC%89%EF%BC%9A111032%EF%BC%8E
25、李莉，徐晓梅，黄婷婷，等．慢性阻塞性肺疾病急性加重期患者不同炎症表型对肺功能的影响［J］．皖南医学院学报，2024，43（2）：142-145．李莉，徐晓梅，黄婷婷，等．慢性阻塞性肺疾病急性加重期患者不同炎症表型对肺功能的影响［J］．皖南医学院学报，2024，43（2）：142-145．
26、GREULICH%E2%80%83T%EF%BC%8CT%C3%9CFFERS%E2%80%83J%EF%BC%8CMAGER%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AHigh%E2%80%83%20eosinophil%E2%80%83%20blood%E2%80%83%20counts%E2%80%83%20are%E2%80%83%20associated%E2%80%83with%E2%80%83%20a%E2%80%83%0Ashorter%E2%80%83length%E2%80%83of%E2%80%83%20hospital%E2%80%83%20stay%E2%80%83in%E2%80%83exacerbated%E2%80%83COPD%E2%80%83%0Apatients%E2%80%83-%E2%80%83a%E2%80%83retrospective%E2%80%83analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERespir%E2%80%83Res%EF%BC%8C%0A2020%EF%BC%8C21%EF%BC%881%EF%BC%89%EF%BC%9A106%EF%BC%8EGREULICH%E2%80%83T%EF%BC%8CT%C3%9CFFERS%E2%80%83J%EF%BC%8CMAGER%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AHigh%E2%80%83%20eosinophil%E2%80%83%20blood%E2%80%83%20counts%E2%80%83%20are%E2%80%83%20associated%E2%80%83with%E2%80%83%20a%E2%80%83%0Ashorter%E2%80%83length%E2%80%83of%E2%80%83%20hospital%E2%80%83%20stay%E2%80%83in%E2%80%83exacerbated%E2%80%83COPD%E2%80%83%0Apatients%E2%80%83-%E2%80%83a%E2%80%83retrospective%E2%80%83analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERespir%E2%80%83Res%EF%BC%8C%0A2020%EF%BC%8C21%EF%BC%881%EF%BC%89%EF%BC%9A106%EF%BC%8E
27、廖艺璇，郭岩斐．《慢性阻塞性肺疾病全球创议（2024版）》解读：嗜酸性粒细胞和2型炎症［J］．国际呼吸杂志，2024，44（6）：637-642．廖艺璇，郭岩斐．《慢性阻塞性肺疾病全球创议（2024版）》解读：嗜酸性粒细胞和2型炎症［J］．国际呼吸杂志，2024，44（6）：637-642．
28、张亚光，孙兵．二型免疫细胞（Th2/ILC2）在肺部过敏性炎症中作用机制的研究进展［J］．中国免疫学杂志，2024，40（1）：11-20．张亚光，孙兵．二型免疫细胞（Th2/ILC2）在肺部过敏性炎症中作用机制的研究进展［J］．中国免疫学杂志，2024，40（1）：11-20．
29、%E2%80%83%20MASPERO%E2%80%83J%EF%BC%8CADIR%E2%80%83Y%EF%BC%8CAL-AHMAD%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EType%E2%80%83%0A2%E2%80%83inflammation%E2%80%83in%E2%80%83asthma%E2%80%83and%E2%80%83other%E2%80%83airway%E2%80%83diseases%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EERJ%E2%80%83Open%E2%80%83Res%EF%BC%8C2022%EF%BC%8C8%EF%BC%883%EF%BC%89%EF%BC%9A00576-%0A02021%EF%BC%8E%E2%80%83%20MASPERO%E2%80%83J%EF%BC%8CADIR%E2%80%83Y%EF%BC%8CAL-AHMAD%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8EType%E2%80%83%0A2%E2%80%83inflammation%E2%80%83in%E2%80%83asthma%E2%80%83and%E2%80%83other%E2%80%83airway%E2%80%83diseases%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EERJ%E2%80%83Open%E2%80%83Res%EF%BC%8C2022%EF%BC%8C8%EF%BC%883%EF%BC%89%EF%BC%9A00576-%0A02021%EF%BC%8E
30、刘晴雨，吴天凤．血嗜酸性粒细胞与慢性阻塞性肺疾病关系研究进展［J］．浙江医学，2022，44（11）：1231-1233．刘晴雨，吴天凤．血嗜酸性粒细胞与慢性阻塞性肺疾病关系研究进展［J］．浙江医学，2022，44（11）：1231-1233．
31、%E2%80%83%20LIU%E2%80%83H%EF%BC%8CXIE%E2%80%83Y%EF%BC%8CHUANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83association%E2%80%83%0Abetween%E2%80%83%20blood%E2%80%83%20eosinophils%E2%80%83%20and%E2%80%83%20clinical%E2%80%83%20outcome%E2%80%83%20of%E2%80%83%0Aacute%E2%80%83exacerbations%E2%80%83of%E2%80%83chronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83%0Adisease%EF%BC%9AA%E2%80%83systematic%E2%80%83review%E2%80%83and%E2%80%83meta-analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ARespir%E2%80%83Med%EF%BC%8C2024%EF%BC%88222%EF%BC%89%EF%BC%9A107501%EF%BC%8E%E2%80%83%20LIU%E2%80%83H%EF%BC%8CXIE%E2%80%83Y%EF%BC%8CHUANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83association%E2%80%83%0Abetween%E2%80%83%20blood%E2%80%83%20eosinophils%E2%80%83%20and%E2%80%83%20clinical%E2%80%83%20outcome%E2%80%83%20of%E2%80%83%0Aacute%E2%80%83exacerbations%E2%80%83of%E2%80%83chronic%E2%80%83obstructive%E2%80%83pulmonary%E2%80%83%0Adisease%EF%BC%9AA%E2%80%83systematic%E2%80%83review%E2%80%83and%E2%80%83meta-analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ARespir%E2%80%83Med%EF%BC%8C2024%EF%BC%88222%EF%BC%89%EF%BC%9A107501%EF%BC%8E
32、李龙，胡振红，刘海潮，等．慢性阻塞性肺疾病患者血嗜酸粒细胞分布及临床特征分析［J］．临床肺科杂志，2023，28（10）：1518-1522．李龙，胡振红，刘海潮，等．慢性阻塞性肺疾病患者血嗜酸粒细胞分布及临床特征分析［J］．临床肺科杂志，2023，28（10）：1518-1522．
33、刘土轩，彭敏，刘旺，等．外周血嗜酸性粒细胞计数与慢性阻塞性肺疾病急性加重期患者呼出气一氧化氮及预后的相关性［J］．中国老年学杂志，2023，43（4）：817-821．刘土轩，彭敏，刘旺，等．外周血嗜酸性粒细胞计数与慢性阻塞性肺疾病急性加重期患者呼出气一氧化氮及预后的相关性［J］．中国老年学杂志，2023，43（4）：817-821．
表示，两组间比较采用独立样本t/t’检验进行分析；非正态分布资料或等级资料采用M（P25，P75）表示，两组间比较采用Mann-Whitney U检验进行分析；相关分析采用Spearman秩相关；计数资料采用例数及百分比（n，%）表示，两组间率的比较采用χ 2 检验或者确切概率法。检验水准为α=0.05。
